pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-383 |
Genomic Coordinates | chr8: 14853438 - 14853510 |
Synonyms | MIRN383, hsa-mir-383, MIR383 |
Description | Homo sapiens miR-383 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-383-5p | |||||||||||||||||||||||||||||||||||||||||||||
Sequence | 7| AGAUCAGAAGGUGAUUGUGGCU |28 | |||||||||||||||||||||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||||||||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
|||||||||||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | CCND1 | ||||||||||||||||||||
Synonyms | BCL1, D11S287E, PRAD1, U21B31 | ||||||||||||||||||||
Description | cyclin D1 | ||||||||||||||||||||
Transcript | NM_053056 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on CCND1 | |||||||||||||||||||||
3'UTR of CCND1 (miRNA target sites are highlighted) |
>CCND1|NM_053056|3'UTR 1 GGGCGCCAGGCAGGCGGGCGCCACCGCCACCCGCAGCGAGGGCGGAGCCGGCCCCAGGTGCTCCCCTGACAGTCCCTCCT 81 CTCCGGAGCATTTTGATACCAGAAGGGAAAGCTTCATTCTCCTTGTTGTTGGTTGTTTTTTCCTTTGCTCTTTCCCCCTT 161 CCATCTCTGACTTAAGCAAAAGAAAAAGATTACCCAAAAACTGTCTTTAAAAGAGAGAGAGAGAAAAAAAAAATAGTATT 241 TGCATAACCCTGAGCGGTGGGGGAGGAGGGTTGTGCTACAGATGATAGAGGATTTTATACCCCAATAATCAACTCGTTTT 321 TATATTAATGTACTTGTTTCTCTGTTGTAAGAATAGGCATTAACACAAAGGAGGCGTCTCGGGAGAGGATTAGGTTCCAT 401 CCTTTACGTGTTTAAAAAAAAGCATAAAAACATTTTAAAAACATAGAAAAATTCAGCAAACCATTTTTAAAGTAGAAGAG 481 GGTTTTAGGTAGAAAAACATATTCTTGTGCTTTTCCTGATAAAGCACAGCTGTAGTGGGGTTCTAGGCATCTCTGTACTT 561 TGCTTGCTCATATGCATGTAGTCACTTTATAAGTCATTGTATGTTATTATATTCCGTAGGTAGATGTGTAACCTCTTCAC 641 CTTATTCATGGCTGAAGTCACCTCTTGGTTACAGTAGCGTAGCGTGCCCGTGTGCATGTCCTTTGCGCCTGTGACCACCA 721 CCCCAACAAACCATCCAGTGACAAACCATCCAGTGGAGGTTTGTCGGGCACCAGCCAGCGTAGCAGGGTCGGGAAAGGCC 801 ACCTGTCCCACTCCTACGATACGCTACTATAAAGAGAAGACGAAATAGTGACATAATATATTCTATTTTTATACTCTTCC 881 TATTTTTGTAGTGACCTGTTTATGAGATGCTGGTTTTCTACCCAACGGCCCTGCAGCCAGCTCACGTCCAGGTTCAACCC 961 ACAGCTACTTGGTTTGTGTTCTTCTTCATATTCTAAAACCATTCCATTTCCAAGCACTTTCAGTCCAATAGGTGTAGGAA 1041 ATAGCGCTGTTTTTGTTGTGTGTGCAGGGAGGGCAGTTTTCTAATGGAATGGTTTGGGAATATCCATGTACTTGTTTGCA 1121 AGCAGGACTTTGAGGCAAGTGTGGGCCACTGTGGTGGCAGTGGAGGTGGGGTGTTTGGGAGGCTGCGTGCCAGTCAAGAA 1201 GAAAAAGGTTTGCATTCTCACATTGCCAGGATGATAAGTTCCTTTCCTTTTCTTTAAAGAAGTTGAAGTTTAGGAATCCT 1281 TTGGTGCCAACTGGTGTTTGAAAGTAGGGACCTCAGAGGTTTACCTAGAGAACAGGTGGTTTTTAAGGGTTATCTTAGAT 1361 GTTTCACACCGGAAGGTTTTTAAACACTAAAATATATAATTTATAGTTAAGGCTAAAAAGTATATTTATTGCAGAGGATG 1441 TTCATAAGGCCAGTATGATTTATAAATGCAATCTCCCCTTGATTTAAACACACAGATACACACACACACACACACACACA 1521 CAAACCTTCTGCCTTTGATGTTACAGATTTAATACAGTTTATTTTTAAAGATAGATCCTTTTATAGGTGAGAAAAAAACA 1601 ATCTGGAAGAAAAAAACCACACAAAGACATTGATTCAGCCTGTTTGGCGTTTCCCAGAGTCATCTGATTGGACAGGCATG 1681 GGTGCAAGGAAAATTAGGGTACTCAACCTAAGTTCGGTTCCGATGAATTCTTATCCCCTGCCCCTTCCTTTAAAAAACTT 1761 AGTGACAAAATAGACAATTTGCACATCTTGGCTATGTAATTCTTGTAATTTTTATTTAGGAAGTGTTGAAGGGAGGTGGC 1841 AAGAGTGTGGAGGCTGACGTGTGAGGGAGGACAGGCGGGAGGAGGTGTGAGGAGGAGGCTCCCGAGGGGAAGGGGCGGTG 1921 CCCACACCGGGGACAGGCCGCAGCTCCATTTTCTTATTGCGCTGCTACCGTTGACTTCCAGGCACGGTTTGGAAATATTC 2001 ACATCGCTTCTGTGTATCTCTTTCACATTGTTTGCTGCTATTGGAGGATCAGTTTTTTGTTTTACAATGTCATATACTGC 2081 CATGTACTAGTTTTAGTTTTCTCTTAGAACATTGTATTACAGATGCCTTTTTTGTAGTTTTTTTTTTTTTTATGTGATCA 2161 ATTTTGACTTAATGTGATTACTGCTCTATTCCAAAAAGGTTGCTGTTTCACAATACCTCATGCTTCACTTAGCCATGGTG 2241 GACCCAGCGGGCAGGTTCTGCCTGCTTTGGCGGGCAGACACGCGGGCGCGATCCCACACAGGCTGGCGGGGGCCGGCCCC 2321 GAGGCCGCGTGCGTGAGAACCGCGCCGGTGTCCCCAGAGACCAGGCTGTGTCCCTCTTCTCTTCCCTGCGCCTGTGATGC 2401 TGGGCACTTCATCTGATCGGGGGCGTAGCATCATAGTAGTTTTTACAGCTGTGTTATTCTTTGCGTGTAGCTATGGAAGT 2481 TGCATAATTATTATTATTATTATTATAACAAGTGTGTCTTACGTGCCACCACGGCGTTGTACCTGTAGGACTCTCATTCG 2561 GGATGATTGGAATAGCTTCTGGAATTTGTTCAAGTTTTGGGTATGTTTAATCTGTTATGTACTAGTGTTCTGTTTGTTAT 2641 TGTTTTGTTAATTACACCATAATGCTAATTTAAAGAGACTCCAAATCTCAATGAAGCCAGCTCACAGTGCTGTGTGCCCC 2721 GGTCACCTAGCAAGCTGCCGAACCAAAAGAATTTGCACCCCGCTGCGGGCCCACGTGGTTGGGGCCCTGCCCTGGCAGGG 2801 TCATCCTGTGCTCGGAGGCCATCTCGGGCACAGGCCCACCCCGCCCCACCCCTCCAGAACACGGCTCACGCTTACCTCAA 2881 CCATCCTGGCTGCGGCGTCTGTCTGAACCACGCGGGGGCCTTGAGGGACGCTTTGTCTGTCGTGATGGGGCAAGGGCACA 2961 AGTCCTGGATGTTGTGTGTATCGAGAGGCCAAAGGCTGGTGGCAAGTGCACGGGGCACAGCGGAGTCTGTCCTGTGACGC 3041 GCAAGTCTGAGGGTCTGGGCGGCGGGCGGCTGGGTCTGTGCATTTCTGGTTGCACCGCGGCGCTTCCCAGCACCAACATG 3121 TAACCGGCATGTTTCCAGCAGAAGACAAAAAGACAAACATGAAAGTCTAGAAATAAAACTGGTAAAACCCCAAAAAAAAA 3201 AAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | NT2 |
Location of target site | 3'UTR |
Tools used in this research | RNA22 |
Original Description (Extracted from the article) |
...
"In this study
... - Tian H; Cao YX; Zhang XS; Liao WP; Yi YH; et al., 2013, Cell death & disease. |
Article |
- Tian H; Cao YX; Zhang XS; Liao WP; Yi YH; et al. - Cell death & disease, 2013
Our previous studies have shown that microRNA-383 (miR-383) expression is downregulated in the testes of infertile men with maturation arrest (MA). Abnormal testicular miR-383 expression may potentiate the connections between male infertility and testicular germ cell tumors. However, the mechanisms underlying the targeting and functions of miR-383 during spermatogenesis remain unknown. In this study, we found that fragile X mental retardation protein (FMRP) was associated with 88 miRNAs in mouse testis including miR-383. Knockdown of FMRP in NTERA-2 (NT2) (testicular embryonal carcinoma) cells enhanced miR-383-induced suppression of cell proliferation by decreasing the interaction between FMRP and miR-383, and then affecting miR-383 binding to the 3'-untranslated region of its target genes, including interferon regulatory factor-1 (IRF1) and Cyclin D1 both in vivo and in vitro. On the other hand, FMRP levels were also downregulated by overexpression of miR-383 in NT2 cells and GC1 (spermatogonia germ cell line). miR-383 targeted to Cyclin D1 directly, and then inhibited its downstream effectors, including phosphorylated pRb and E2F1, which ultimately resulted in decreased FMRP expression. Reduced miR-383 expression, dysregulated cyclin-dependent kinase 4 expression (one of the downstream genes of miR-383) and increased DNA damage were also observed in the testes of Fmr1 knockout mice and of MA patients with a downregulation of FMRP. A potential feedback loop between FMRP and miR-383 during spermatogenesis is proposed, and FMRP acts as a negative regulator of miR-383 functions. Our data also indicate that dysregulation of the FMRP-miR-383 pathway may partially contribute to human spermatogenic failure with MA.
LinkOut: [PMID: 23640459]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | U251 , U87/WT | ||||||
Disease | MIMAT0000738 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan | ||||||
Original Description (Extracted from the article) |
...
"Meanwhile
... - Xu Z; Zeng X; Tian D; Xu H; Cai Q; Wang J; Chen Q, 2014, Biochemical and biophysical research communications. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Xu Z; Zeng X; Tian D; Xu H; Cai Q; Wang J; Chen Q - Biochemical and biophysical research communications, 2014
In recent years, microRNAs (miRNAs) have been proved to be closely related to the tumorigenesis and progression. An increasing number of researches have shown that microRNAs function as oncogenes or tumor suppressor genes in human malignant tumors. This study aims to explore the effects of microRNA-383 (miR-383) on malignant biological function of human gliomas. We detected the expression of miR-383 in glioma tissues and normal brain tissues by quantitative real-time PCR. Anchorage-independent growth assays, and flow cytometry were used to evaluate the functions of miR-383 that involves in cell growth and cell cycle. Western blotting assay was used to examine protein expression levels of Cyclin D1 (CCND1), a cell cycle-associated oncogene which has a predicted binding site of miR-383 within its 3'-untranslated region (3'-UTR), and luciferase activity assay was used to evaluate the 3'-UTR activity of CCND1. In this study, we found that miR-383 expression level was lower in gliomas than normal brain tissues. Overexpression of miR-383 in U251 and U87 cells showed a significant inhibitory effect on cell growth, which accompanied with cell cycle G0/G1 arrest as well as downregulation of CCND1 expression. Moreover, CCND1 was verified to be one of the direct targets of miR-383. In summary, this study suggested that miR-383 plays the role of tumor suppressor by targeting CCND1 in glioma cells, and may be useful for developing a new therapeutic strategy for gliomas.
LinkOut: [PMID: 25450356]
|
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
96 hsa-miR-383-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT004443 | VEGFA | vascular endothelial growth factor A | 5 | 2 | ||||||||
MIRT006137 | DIO1 | iodothyronine deiodinase 1 | 3 | 1 | ||||||||
MIRT006535 | IRF1 | interferon regulatory factor 1 | 3 | 1 | ||||||||
MIRT007246 | IGF1R | insulin like growth factor 1 receptor | 1 | 1 | ||||||||
MIRT007305 | PRDX3 | peroxiredoxin 3 | 1 | 1 | ||||||||
MIRT054359 | CCND1 | cyclin D1 | 4 | 2 | ||||||||
MIRT057087 | DDIT4 | DNA damage inducible transcript 4 | 2 | 2 | ||||||||
MIRT086536 | HSPE1-MOB4 | HSPE1-MOB4 readthrough | 2 | 2 | ||||||||
MIRT086544 | MOB4 | MOB family member 4, phocein | 2 | 2 | ||||||||
MIRT438194 | PPP1R10 | protein phosphatase 1 regulatory subunit 10 | 3 | 1 | ||||||||
MIRT448282 | ZMYM2 | zinc finger MYM-type containing 2 | 2 | 2 | ||||||||
MIRT451601 | TRPM7 | transient receptor potential cation channel subfamily M member 7 | 2 | 2 | ||||||||
MIRT453387 | RHD | Rh blood group D antigen | 2 | 2 | ||||||||
MIRT458521 | C5orf22 | chromosome 5 open reading frame 22 | 2 | 2 | ||||||||
MIRT459720 | SGK494 | uncharacterized serine/threonine-protein kinase SgK494 | 2 | 2 | ||||||||
MIRT461491 | KIAA1009 | centrosomal protein 162 | 1 | 1 | ||||||||
MIRT463261 | ZIC5 | Zic family member 5 | 2 | 2 | ||||||||
MIRT464237 | VCP | valosin containing protein | 2 | 2 | ||||||||
MIRT465320 | TRAF5 | TNF receptor associated factor 5 | 2 | 2 | ||||||||
MIRT465774 | TMOD3 | tropomodulin 3 | 2 | 2 | ||||||||
MIRT467879 | SLC22A23 | solute carrier family 22 member 23 | 2 | 2 | ||||||||
MIRT469636 | RAD21 | RAD21 cohesin complex component | 2 | 6 | ||||||||
MIRT472041 | NPAT | nuclear protein, coactivator of histone transcription | 2 | 2 | ||||||||
MIRT476568 | GABARAPL1 | GABA type A receptor associated protein like 1 | 2 | 2 | ||||||||
MIRT478586 | CTDSPL2 | CTD small phosphatase like 2 | 2 | 2 | ||||||||
MIRT478870 | CREBRF | CREB3 regulatory factor | 2 | 2 | ||||||||
MIRT482202 | AHR | aryl hydrocarbon receptor | 2 | 2 | ||||||||
MIRT484237 | IER2 | immediate early response 2 | 2 | 2 | ||||||||
MIRT487480 | NRF1 | nuclear respiratory factor 1 | 2 | 6 | ||||||||
MIRT493746 | GRAP2 | GRB2-related adaptor protein 2 | 2 | 2 | ||||||||
MIRT496836 | ZNF460 | zinc finger protein 460 | 2 | 2 | ||||||||
MIRT497234 | APOL2 | apolipoprotein L2 | 2 | 2 | ||||||||
MIRT499424 | PLCG2 | phospholipase C gamma 2 | 2 | 9 | ||||||||
MIRT500598 | UBN2 | ubinuclein 2 | 2 | 10 | ||||||||
MIRT502859 | CHEK2 | checkpoint kinase 2 | 2 | 6 | ||||||||
MIRT507727 | CLIC4 | chloride intracellular channel 4 | 2 | 4 | ||||||||
MIRT510509 | YOD1 | YOD1 deubiquitinase | 2 | 6 | ||||||||
MIRT511901 | FNBP1L | formin binding protein 1 like | 2 | 6 | ||||||||
MIRT514393 | CLUAP1 | clusterin associated protein 1 | 2 | 2 | ||||||||
MIRT520180 | WBP2 | WW domain binding protein 2 | 2 | 4 | ||||||||
MIRT531214 | PLA2G4D | phospholipase A2 group IVD | 2 | 2 | ||||||||
MIRT532846 | ZNF699 | zinc finger protein 699 | 2 | 2 | ||||||||
MIRT533461 | TRIM71 | tripartite motif containing 71 | 2 | 2 | ||||||||
MIRT539263 | ANKRD44 | ankyrin repeat domain 44 | 2 | 2 | ||||||||
MIRT539380 | ADSS | adenylosuccinate synthase | 2 | 6 | ||||||||
MIRT548129 | GAS1 | growth arrest specific 1 | 2 | 2 | ||||||||
MIRT550662 | ZFP37 | ZFP37 zinc finger protein | 2 | 2 | ||||||||
MIRT551499 | CENPN | centromere protein N | 2 | 2 | ||||||||
MIRT553778 | TAF13 | TATA-box binding protein associated factor 13 | 2 | 2 | ||||||||
MIRT554376 | SFPQ | splicing factor proline and glutamine rich | 2 | 2 | ||||||||
MIRT555821 | PCDH11Y | protocadherin 11 Y-linked | 2 | 4 | ||||||||
MIRT557558 | GOSR1 | golgi SNAP receptor complex member 1 | 2 | 2 | ||||||||
MIRT557694 | GATA6 | GATA binding protein 6 | 2 | 2 | ||||||||
MIRT561383 | TWF1 | twinfilin actin binding protein 1 | 2 | 2 | ||||||||
MIRT561414 | TSN | translin | 2 | 2 | ||||||||
MIRT561867 | MSH6 | mutS homolog 6 | 2 | 2 | ||||||||
MIRT567383 | GTPBP3 | GTP binding protein 3, mitochondrial | 2 | 2 | ||||||||
MIRT569272 | PCDH11X | protocadherin 11 X-linked | 2 | 2 | ||||||||
MIRT569556 | UNC119B | unc-119 lipid binding chaperone B | 2 | 2 | ||||||||
MIRT569760 | RIMBP3C | RIMS binding protein 3C | 2 | 5 | ||||||||
MIRT573387 | GGA2 | golgi associated, gamma adaptin ear containing, ARF binding protein 2 | 2 | 2 | ||||||||
MIRT573456 | RPL41 | ribosomal protein L41 | 2 | 2 | ||||||||
MIRT573968 | DDX21 | DExD-box helicase 21 | 2 | 2 | ||||||||
MIRT574163 | ATG10 | autophagy related 10 | 2 | 2 | ||||||||
MIRT574659 | KLHL15 | kelch like family member 15 | 2 | 2 | ||||||||
MIRT574907 | Plcg2 | phospholipase C, gamma 2 | 2 | 6 | ||||||||
MIRT607496 | HEBP2 | heme binding protein 2 | 2 | 2 | ||||||||
MIRT612840 | KCNJ12 | potassium voltage-gated channel subfamily J member 12 | 2 | 4 | ||||||||
MIRT613962 | TMEM59 | transmembrane protein 59 | 2 | 2 | ||||||||
MIRT621125 | PCNXL2 | pecanex homolog 2 | 2 | 2 | ||||||||
MIRT625216 | SH3TC2 | SH3 domain and tetratricopeptide repeats 2 | 2 | 2 | ||||||||
MIRT643337 | MICA | MHC class I polypeptide-related sequence A | 2 | 2 | ||||||||
MIRT646342 | CLIC6 | chloride intracellular channel 6 | 2 | 2 | ||||||||
MIRT647361 | WDR5B | WD repeat domain 5B | 2 | 2 | ||||||||
MIRT650308 | SLC35E2 | solute carrier family 35 member E2 | 2 | 2 | ||||||||
MIRT651372 | ZBTB21 | zinc finger and BTB domain containing 21 | 2 | 2 | ||||||||
MIRT655301 | PEAR1 | platelet endothelial aggregation receptor 1 | 2 | 2 | ||||||||
MIRT681918 | SLC11A2 | solute carrier family 11 member 2 | 2 | 2 | ||||||||
MIRT684165 | ALDH1B1 | aldehyde dehydrogenase 1 family member B1 | 2 | 2 | ||||||||
MIRT688053 | GLUL | glutamate-ammonia ligase | 2 | 2 | ||||||||
MIRT690210 | C5orf45 | MRN complex interacting protein | 2 | 2 | ||||||||
MIRT691024 | CRTC3 | CREB regulated transcription coactivator 3 | 2 | 2 | ||||||||
MIRT697699 | WAC | WW domain containing adaptor with coiled-coil | 2 | 2 | ||||||||
MIRT698201 | TMEM30A | transmembrane protein 30A | 2 | 2 | ||||||||
MIRT698857 | SRSF2 | serine and arginine rich splicing factor 2 | 2 | 2 | ||||||||
MIRT702292 | LDHA | lactate dehydrogenase A | 4 | 2 | ||||||||
MIRT703341 | GDPD5 | glycerophosphodiester phosphodiesterase domain containing 5 | 2 | 2 | ||||||||
MIRT704082 | DYRK2 | dual specificity tyrosine phosphorylation regulated kinase 2 | 2 | 2 | ||||||||
MIRT713729 | SUCO | SUN domain containing ossification factor | 2 | 2 | ||||||||
MIRT719487 | RBM27 | RNA binding motif protein 27 | 2 | 2 | ||||||||
MIRT722080 | SMC2 | structural maintenance of chromosomes 2 | 2 | 2 | ||||||||
MIRT724102 | TMEM199 | transmembrane protein 199 | 2 | 2 | ||||||||
MIRT725124 | SYNRG | synergin gamma | 2 | 2 | ||||||||
MIRT725601 | CAPN6 | calpain 6 | 2 | 2 | ||||||||
MIRT737186 | RBM3 | RNA binding motif (RNP1, RRM) protein 3 | 4 | 0 | ||||||||
MIRT755379 | NOS3 | nitric oxide synthase 3 | 3 | 1 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|